Looking at Athira Pharma, Inc.'s (NASDAQ:ATHA ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders ...

BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ...

BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ...

Athira conducted the first-in-human Phase 1 (NCT 06432647) double-blind, placebo-controlled clinical trial that enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses ...

As at September 2024, Athira Pharma had cash of US$69m and no debt. In the last year, its cash burn was US$97m. Therefore, from September 2024 it had roughly 8 months of cash runway.

The Thiruvananthapuram Rural police believe they have zeroed in on the suspect in the fatal stabbing of Athira, 33, a housewife and mother of a two-year-old child, at her residence at Kadinamkulam ...

Seattle-area biotech company Athira Pharma agreed to pay $4.07 million to settle allegations that it violated the False Claims Act by failing to disclose research misconduct to federal agencies in ...

Insider Ownership Of Athira Pharma Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder ...

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc ...

The layoffs are expected to affect about 49 employees and will cost Athira about $2.8 million in the near term while leading to savings of approximately $13.4 million on an annual basis. The moves ...

Athira CEO Mark Litton. (Athira Photo) Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.